Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2021 · 10-Q
Revenue$8.06M$8.06M−2.3% vs Q3 2020 Net Income-$3.56M-$3.56MN/M vs Q3 2020 EPS Diluted-$0.85-$0.85N/M vs Q3 2020 Gross Profit$4,437,000+45.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$676,000N/M Free Cash Flowderived-$820,000N/M Margins · derivedGross margin55.1%+18.0 pt vs Q3 2020
Operating margin-22.7%+50.2 pt vs Q3 2020
Net margin-44.2%+31.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end